Rhumbline Advisers Eliem Therapeutics, Inc. Transaction History
Rhumbline Advisers
- $109 Billion
- Q4 2024
A detailed history of Rhumbline Advisers transactions in Eliem Therapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 31,836 shares of ELYM stock, worth $130,845. This represents 0.0% of its overall portfolio holdings.
Number of Shares
31,836
Previous 27,740
14.77%
Holding current value
$130,845
Previous $141,000
7.8%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding ELYM
# of Institutions
76Shares Held
51MCall Options Held
0Put Options Held
0-
Ra Capital Management, L.P. Boston, MA31.4MShares$129 Million2.09% of portfolio
-
Janus Henderson Group PLC London, X03.18MShares$13.1 Million0.01% of portfolio
-
Samsara Bio Capital, LLC Palo Alto, CA2.61MShares$10.7 Million3.29% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.51MShares$6.19 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT1.04MShares$4.27 Million0.19% of portfolio
About Eliem Therapeutics, Inc.
- Ticker ELYM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,567,700
- Market Cap $109M
- Description
- Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase II...